Page 4 - கல்லூரி ஆஃப் அமெரிக்கன் நோயியல் நிபுணர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion . Burning Rock Biotech LimitedAugust 3, 2021 GMT GUANGZHOU, China, Aug. 03, 2021 (GLOBE NEWSWIRE) Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib (IMP4297), a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA). The global program will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Patho

United statesYusheng hanJun baoCollege of american pathologistsDrug administrationBurning rock clinical laboratory improvement amendmentsCenters for medicareCompany or burning rockBurning rock biotech limitedSecurities exchangeNational medical products administration of chinaMedicaid servicesRock biotech limitedNational medical products administrationBurning rockClinical laboratory improvement amendments